99 related articles for article (PubMed ID: 2859924)
1. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
[No Abstract] [Full Text] [Related]
4. Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.
Lawton JO; Giles GR; Hall J; MacAdam A; Hall R; Matheson T; Bird G
Cancer Treat Rep; 1981; 65(1-2):13-15. PubMed ID: 6452945
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Rosenthal S; Harris DT; Horton J; Glick JH
Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
[TBL] [Abstract][Full Text] [Related]
6. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Moertel CG; Lefkopoulo M; Lipsitz S; Hahn RG; Klaassen D
N Engl J Med; 1992 Feb; 326(8):519-23. PubMed ID: 1310159
[TBL] [Abstract][Full Text] [Related]
7. Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Blum RH; Kahlert T
Cancer Treat Rep; 1978 Mar; 62(3):435-8. PubMed ID: 348312
[TBL] [Abstract][Full Text] [Related]
8. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Neidhart JA; Laufman LR; Vaughn C; McCracken JD
Cancer Treat Rep; 1980; 64(4-5):675-7. PubMed ID: 7427953
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of maytansine in patients with advanced colorectal carcinoma.
O'Connell MJ; Shani A; Rubin J; Moertel CG
Cancer Treat Rep; 1978 Aug; 62(8):1237-8. PubMed ID: 356981
[No Abstract] [Full Text] [Related]
10. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of chlorozotocin.
Gralla RJ; Tan CT; Young CW
Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
[TBL] [Abstract][Full Text] [Related]
13. Initial clinical trials of maytansine, an antitumor plant alkaloid.
Chabner BA; Levine AS; Johnson BL; Young RC
Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of maytansine in patients with metastatic lung cancer.
Eagan RT; Creagan ET; Ingle JN; Frytak S; Rubin J
Cancer Treat Rep; 1978 Oct; 62(10):1577-9. PubMed ID: 709559
[No Abstract] [Full Text] [Related]
15. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of chlorozotocin in patients with malignant melanoma.
Houghton AN; Camacho FJ; Gralla RJ; Wittes R
Cancer Treat Rep; 1981; 65(7-8):705-6. PubMed ID: 6454487
[No Abstract] [Full Text] [Related]
18. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
Smith FP; Rustgi VK; Schertz G; Woolley PV; Schein PS
Cancer Treat Rep; 1982 Dec; 66(12):2095-6. PubMed ID: 6215982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
